Dashboard
1
Poor Management Efficiency with a low ROE of 5.46%
- The company has been able to generate a Return on Equity (avg) of 5.46% signifying low profitability per unit of shareholders funds
2
Positive results in Dec 24
3
With ROE of 7.61%, it has a very expensive valuation with a 4.57 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.23%
0%
13.23%
6 Months
16.23%
0%
16.23%
1 Year
1.45%
0%
1.45%
2 Years
12.32%
0%
12.32%
3 Years
97.75%
0%
97.75%
4 Years
112.73%
0%
112.73%
5 Years
164.91%
0%
164.91%
Niox Group Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.92%
EBIT Growth (5y)
19.99%
EBIT to Interest (avg)
-1.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
0.46
Tax Ratio
56.41%
Dividend Payout Ratio
142.05%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
4.78%
ROE (avg)
5.46%
Valuation key factors
Factor
Value
P/E Ratio
60
Industry P/E
Price to Book Value
4.57
EV to EBIT
30.46
EV to EBITDA
20.99
EV to Capital Employed
5.33
EV to Sales
6.16
PEG Ratio
NA
Dividend Yield
14.25%
ROCE (Latest)
17.48%
ROE (Latest)
7.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
36.80
31.30
17.57%
Operating Profit (PBDIT) excl Other Income
9.00
6.40
40.62%
Interest
0.20
0.30
-33.33%
Exceptional Items
0.00
8.00
-100.00%
Consolidate Net Profit
9.50
14.10
-32.62%
Operating Profit Margin (Excl OI)
125.00%
57.50%
6.75%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 17.57% vs 12.19% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -32.62% vs 513.04% in Dec 2022
About Niox Group Plc 
Niox Group Plc
Pharmaceuticals & Biotechnology
Circassia Group Plc, formerly Circassia Pharmaceuticals Plc, is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company is primarily focused on offering its commercialized asthma management products directly to specialist physicians in various markets. The Company’s NIOX products are used to improve asthma and offers a portfolio of asthma and chronic obstructive pulmonary disease product candidates. The Company’s commercialized chronic obstructive pulmonary disease (COPD) products are Tudorza and Duaklir in the United States. The Company’s pipeline products also include late-stage nitric oxide product LungFit PH, which is a ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air.
Company Coordinates 
Company Details
Northbrook House, Robert Robinson Avenue , OXFORD None : OX4 4GA
Registrar Details






